{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:04:32Z","timestamp":1787785472045,"version":"build-2784847793"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T00:00:00Z","timestamp":1540598400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170485, 81170488, 81370657, and 81470328"],"award-info":[{"award-number":["81170485, 81170488, 81370657, and 81470328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key Projects of the Health Department of Jiangsu Province","award":["K201108"],"award-info":[{"award-number":["K201108"]}]},{"name":"Jiangsu Province\u2019s Medical Elite Programme","award":["RC2011169"],"award-info":[{"award-number":["RC2011169"]}]},{"DOI":"10.13039\/501100014207","name":"the National Public Health Grand Research Foundation","doi-asserted-by":"crossref","award":["201202017"],"award-info":[{"award-number":["201202017"]}],"id":[{"id":"10.13039\/501100014207","id-type":"DOI","asserted-by":"crossref"}]},{"name":"a project funded by the Priority Academic Programme Development of Jiangsu Higher Education Institute","award":["JX10231801"],"award-info":[{"award-number":["JX10231801"]}]},{"name":"Project of National Key Clinical Specialty, the National Science & Technology Pillar Programme","award":["2014BAI09B12"],"award-info":[{"award-number":["2014BAI09B12"]}]},{"name":"a project funded by Jiangsu Provincial Special Programme of Medical Science","award":["BL2014086"],"award-info":[{"award-number":["BL2014086"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s00277-018-3529-9","type":"journal-article","created":{"date-parts":[[2018,10,27]],"date-time":"2018-10-27T04:43:56Z","timestamp":1540615436000},"page":"255-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Circulating tumor DNA: clinical roles in diffuse large B cell lymphoma"],"prefix":"10.1007","volume":"98","author":[{"given":"Fang-Tian","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luo","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4208-7477","authenticated-orcid":false,"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,27]]},"reference":[{"issue":"5","key":"3529_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. \n                    https:\/\/doi.org\/10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"issue":"1","key":"3529_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","volume":"125","author":"LH Sehn","year":"2015","unstructured":"Sehn LH, Gascoyne RD (2015) Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity. Blood 125(1):22\u201332. \n                    https:\/\/doi.org\/10.1182\/blood-2014-05-577189","journal-title":"Blood"},{"issue":"12","key":"3529_CR3","doi-asserted-by":"publisher","first-page":"2094","DOI":"10.1200\/JCO.2009.24.5860","volume":"28","author":"JF Larouche","year":"2010","unstructured":"Larouche JF, Berger F, Chassagne-Clement C et al (2010) Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome. J Clin Oncol 28(12):2094\u20132100. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.24.5860","journal-title":"J Clin Oncol"},{"issue":"4","key":"3529_CR4","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JC Wan","year":"2017","unstructured":"Wan JC, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N (2017) Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer 17(4):223\u2013238. \n                    https:\/\/doi.org\/10.1038\/nrc.2017.7","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3529_CR5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13148-016-0261-y","volume":"8","author":"LS Kristensen","year":"2016","unstructured":"Kristensen LS, Hansen JW, Kristensen SS, Tholstrup D, Harslof LB, Pedersen OB, De Nully Brown P, Gronbaek K (2016) Aberrant methylation of cell-free circulating DNA in plasma predicts poor outcome in diffuse large B cell lymphoma. Clin Epigenetics 8(1):95. \n                    https:\/\/doi.org\/10.1186\/s13148-016-0261-y","journal-title":"Clin Epigenetics"},{"issue":"7","key":"3529_CR6","doi-asserted-by":"publisher","first-page":"e280","DOI":"10.3324\/haematol.2015.123612","volume":"100","author":"E Bohers","year":"2015","unstructured":"Bohers E, Viailly PJ, Dubois S et al (2015) Somatic mutations of cell-free circulating DNA detected by next-generation sequencing reflect the genetic changes in both germinal center B-cell-like and activated B-cell-like diffuse large B-cell lymphomas at the time of diagnosis. Haematologica 100(7):e280\u2013e284. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.123612","journal-title":"Haematologica"},{"issue":"12","key":"3529_CR7","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1093\/annonc\/mdx061","volume":"27","author":"M Ladetto","year":"2017","unstructured":"Ladetto M, Buske C, Hutchings M et al (2017) ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia. Ann Oncol 27(12):2149\u20132160. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx061","journal-title":"Ann Oncol"},{"issue":"2","key":"3529_CR8","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1200\/JCO.2011.38.2648","volume":"30","author":"V Safar","year":"2012","unstructured":"Safar V, Dupuis J, Itti E et al (2012) Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. J Clin Oncol 30(2):184\u2013190. \n                    https:\/\/doi.org\/10.1200\/JCO.2011.38.2648","journal-title":"J Clin Oncol"},{"issue":"12","key":"3529_CR9","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","volume":"34","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Broccoli A, Gioia DM et al (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 study. J Clin Oncol 34(12):1376\u20131385. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.63.0699","journal-title":"J Clin Oncol"},{"issue":"25","key":"3529_CR10","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"374","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 374(25):2419\u20132429. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1510093","journal-title":"N Engl J Med"},{"issue":"11","key":"3529_CR11","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1200\/JCO.2009.26.5942","volume":"28","author":"CH Moskowitz","year":"2010","unstructured":"Moskowitz CH, Schoder H, Teruya-Feldstein J et al (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol 28(11):1896\u20131903. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.26.5942","journal-title":"J Clin Oncol"},{"issue":"13","key":"3529_CR12","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1200\/JCO.2014.60.1120","volume":"33","author":"GA Abel","year":"2015","unstructured":"Abel GA (2015) Does surveillance imaging after treatment for diffuse large B-cell lymphoma really work? J Clin Oncol 33(13):1427\u20131429. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.60.1120","journal-title":"J Clin Oncol"},{"issue":"2","key":"3529_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1007\/s11864-017-0451-7","volume":"18","author":"T Phillips","year":"2017","unstructured":"Phillips T, Mercer J (2017) Surveillance scans in lymphoma: friend or foe? Curr Treat Options in Oncol 18(2):10. \n                    https:\/\/doi.org\/10.1007\/s11864-017-0451-7","journal-title":"Curr Treat Options in Oncol"},{"issue":"14","key":"3529_CR14","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1200\/JCO.2014.60.0627","volume":"33","author":"V Pitini","year":"2015","unstructured":"Pitini V, Arrigo C, Di Mirto C, Garufi L, Mondello P, d\u2019Aquino A, Altavilla G (2015) Should the use of surveillance imaging in diffuse large B-cell lymphoma be discontinued? J Clin Oncol 33(14):1623. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.60.0627","journal-title":"J Clin Oncol"},{"issue":"23","key":"3529_CR15","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1200\/JCO.2014.58.9846","volume":"33","author":"C Mamot","year":"2015","unstructured":"Mamot C, Klingbiel D, Hitz F et al (2015) Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38\/07). J Clin Oncol 33(23):2523\u20132529. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.58.9846","journal-title":"J Clin Oncol"},{"issue":"34","key":"3529_CR16","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1200\/JCO.2015.62.0229","volume":"33","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Jakobsen LH, Hutchings M et al (2015) Routine imaging for diffuse large B-cell lymphoma in first complete remission does not improve post-treatment survival: a Danish-Swedish population-based study. J Clin Oncol 33(34):3993\u20133998. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.62.0229","journal-title":"J Clin Oncol"},{"issue":"8","key":"3529_CR17","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21(8):922\u2013926. \n                    https:\/\/doi.org\/10.1038\/nm.3884","journal-title":"Nat Med"},{"issue":"8","key":"3529_CR18","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Roberts AW, Seymour JF et al (2017) Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma. J Clin Oncol 35(8):826\u2013833. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.70.4320","journal-title":"J Clin Oncol"},{"issue":"1","key":"3529_CR19","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/nrclinonc.2013.197","volume":"11","author":"M Roschewski","year":"2014","unstructured":"Roschewski M, Staudt LM, Wilson WH (2014) Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11(1):12\u201323. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2013.197","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"3529_CR20","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","volume":"128","author":"SE Assouline","year":"2016","unstructured":"Assouline SE, Nielsen TH, Yu S et al (2016) Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma. Blood 128(2):185\u2013194. \n                    https:\/\/doi.org\/10.1182\/blood-2016-02-699520","journal-title":"Blood"},{"key":"3529_CR21","doi-asserted-by":"publisher","unstructured":"Ennishi D, Mottok A, Ben-Neriah S et al (2017) Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell of origin-specific clinical impact. Blood. \n                    https:\/\/doi.org\/10.1182\/blood-2016-11-747022","DOI":"10.1182\/blood-2016-11-747022"},{"issue":"18","key":"3529_CR22","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1182\/blood-2015-09-672352","volume":"127","author":"B Chapuy","year":"2016","unstructured":"Chapuy B, Cheng H, Watahiki A et al (2016) Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease. Blood 127(18):2203\u20132213. \n                    https:\/\/doi.org\/10.1182\/blood-2015-09-672352","journal-title":"Blood"},{"issue":"9","key":"3529_CR23","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","volume":"22","author":"RD Morin","year":"2016","unstructured":"Morin RD, Assouline S, Alcaide M et al (2016) Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas. Clin Cancer Res 22(9):2290\u20132300. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2123","journal-title":"Clin Cancer Res"},{"issue":"1\u20132","key":"3529_CR24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.cell.2015.11.050","volume":"164","author":"MW Snyder","year":"2016","unstructured":"Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J (2016) Cell-free DNA comprises an in vivo nucleosome footprint that informs its tissues-of-origin. Cell 164(1\u20132):57\u201368. \n                    https:\/\/doi.org\/10.1016\/j.cell.2015.11.050","journal-title":"Cell"},{"issue":"6","key":"3529_CR25","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1080\/14737159.2017.1319765","volume":"17","author":"V Camus","year":"2017","unstructured":"Camus V, Jardin F, Tilly H (2017) The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential. Expert Rev Mol Diagn 17(6):557\u2013566. \n                    https:\/\/doi.org\/10.1080\/14737159.2017.1319765","journal-title":"Expert Rev Mol Diagn"},{"issue":"3\u20134","key":"3529_CR26","first-page":"241","volume":"142","author":"P Mandel","year":"1948","unstructured":"Mandel P, Metais P (1948) Les acides nucl\u00e9iques du plasma sanguin chez l\u2019homme. C R Seances Soc Biol Fil 142(3\u20134):241\u2013243","journal-title":"C R Seances Soc Biol Fil"},{"issue":"3","key":"3529_CR27","first-page":"646","volume":"37","author":"SA Leon","year":"1977","unstructured":"Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37(3):646\u2013650","journal-title":"Cancer Res"},{"issue":"5","key":"3529_CR28","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1159\/000226740","volume":"46","author":"M Stroun","year":"1989","unstructured":"Stroun M, Anker P, Maurice P, Lyautey J, Lederrey C, Beljanski M (1989) Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology 46(5):318\u2013322","journal-title":"Oncology"},{"issue":"1","key":"3529_CR29","first-page":"67","volume":"3","author":"GD Sorenson","year":"1994","unstructured":"Sorenson GD, Pribish DM, Valone FH, Memoli VA, Bzik DJ, Yao SL (1994) Soluble normal and mutated DNA sequences from single-copy genes in human blood. Cancer Epidemiol Biomark Prev 3(1):67\u201371","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"45","key":"3529_CR30","doi-asserted-by":"publisher","first-page":"16368","DOI":"10.1073\/pnas.0507904102","volume":"102","author":"F Diehl","year":"2005","unstructured":"Diehl F, Li M, Dressman D et al (2005) Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc Natl Acad Sci U S A 102(45):16368\u201316373. \n                    https:\/\/doi.org\/10.1073\/pnas.0507904102","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3529_CR31","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/nm.1789","volume":"14","author":"F Diehl","year":"2008","unstructured":"Diehl F, Schmidt K, Choti MA et al (2008) Circulating mutant DNA to assess tumor dynamics. Nat Med 14(9):985\u2013990. \n                    https:\/\/doi.org\/10.1038\/nm.1789","journal-title":"Nat Med"},{"issue":"136","key":"3529_CR32","doi-asserted-by":"publisher","first-page":"136ra168","DOI":"10.1126\/scitranslmed.3003726","volume":"4","author":"T Forshew","year":"2012","unstructured":"Forshew T, Murtaza M, Parkinson C et al (2012) Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 4(136):136ra168. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3003726","journal-title":"Sci Transl Med"},{"issue":"5","key":"3529_CR33","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nm.3519","volume":"20","author":"AM Newman","year":"2014","unstructured":"Newman AM, Bratman SV, To J et al (2014) An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 20(5):548\u2013554. \n                    https:\/\/doi.org\/10.1038\/nm.3519","journal-title":"Nat Med"},{"issue":"12","key":"3529_CR34","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1182\/blood.V90.12.4953","volume":"90","author":"N Frickhofen","year":"1997","unstructured":"Frickhofen N, Muller E, Sandherr M, Binder T, Bangerter M, Wiest C, Enz M, Heimpel H (1997) Rearranged Ig heavy chain DNA is detectable in cell-free blood samples of patients with B-cell neoplasia. Blood 90(12):4953\u20134960","journal-title":"Blood"},{"issue":"1\u20132","key":"3529_CR35","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s0009-8981(03)00279-1","volume":"335","author":"U Deligezer","year":"2003","unstructured":"Deligezer U, Yaman F, Erten N, Dalay N (2003) Frequent copresence of methylated DNA and fragmented nucleosomal DNA in plasma of lymphoma patients. Clin Chim Acta 335(1\u20132):89\u201394. \n                    https:\/\/doi.org\/10.1016\/s0009-8981(03)00279-1","journal-title":"Clin Chim Acta"},{"issue":"1","key":"3529_CR36","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/carcin\/bgl092","volume":"28","author":"H Shi","year":"2007","unstructured":"Shi H, Guo J, Duff DJ et al (2007) Discovery of novel epigenetic markers in non-Hodgkin\u2019s lymphoma. Carcinogenesis 28(1):60\u201370. \n                    https:\/\/doi.org\/10.1093\/carcin\/bgl092","journal-title":"Carcinogenesis"},{"issue":"3","key":"3529_CR37","doi-asserted-by":"publisher","first-page":"178","DOI":"10.18632\/oncotarget.235","volume":"2","author":"J He","year":"2011","unstructured":"He J, Wu J, Jiao Y, Wagner-Johnston N, Ambinder RF, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N (2011) IgH gene rearrangements as plasma biomarkers in Non- Hodgkin\u2019s lymphoma patients. Oncotarget 2(3):178\u2013185. \n                    https:\/\/doi.org\/10.18632\/oncotarget.235","journal-title":"Oncotarget"},{"issue":"5","key":"3529_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/s1470-2045(15)70106-3","volume":"16","author":"M Roschewski","year":"2015","unstructured":"Roschewski M, Dunleavy K, Pittaluga S et al (2015) Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol 16(5):541\u2013549. \n                    https:\/\/doi.org\/10.1016\/s1470-2045(15)70106-3","journal-title":"Lancet Oncol"},{"issue":"364","key":"3529_CR39","doi-asserted-by":"publisher","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","volume":"8","author":"F Scherer","year":"2016","unstructured":"Scherer F, Kurtz DM, Newman AM et al (2016) Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA. Sci Transl Med 8(364):364ra155. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aai8545","journal-title":"Sci Transl Med"},{"issue":"24","key":"3529_CR40","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","volume":"125","author":"DM Kurtz","year":"2015","unstructured":"Kurtz DM, Green MR, Bratman SV et al (2015) Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood 125(24):3679\u20133687. \n                    https:\/\/doi.org\/10.1182\/blood-2015-03-635169","journal-title":"Blood"},{"key":"3529_CR41","doi-asserted-by":"publisher","first-page":"14756","DOI":"10.1038\/ncomms14756","volume":"8","author":"P Yeh","year":"2017","unstructured":"Yeh P, Hunter T, Sinha D et al (2017) Circulating tumour DNA reflects treatment response and clonal evolution in chronic lymphocytic leukaemia. Nat Commun 8:14756. \n                    https:\/\/doi.org\/10.1038\/ncomms14756","journal-title":"Nat Commun"},{"issue":"5","key":"3529_CR42","doi-asserted-by":"publisher","first-page":"8765","DOI":"10.18632\/oncotarget.14448","volume":"8","author":"C Sarkozy","year":"2017","unstructured":"Sarkozy C, Huet S, Carlton VE et al (2017) The prognostic value of clonal heterogeneity and quantitative assessment of plasma circulating clonal IG-VDJ sequences at diagnosis in patients with follicular lymphoma. Oncotarget 8(5):8765\u20138774. \n                    https:\/\/doi.org\/10.18632\/oncotarget.14448","journal-title":"Oncotarget"},{"issue":"9","key":"3529_CR43","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.3109\/10428194.2016.1139703","volume":"57","author":"V Camus","year":"2016","unstructured":"Camus V, Sarafan-Vasseur N, Bohers E et al (2016) Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. Leuk Lymphoma 57(9):2171\u20132179. \n                    https:\/\/doi.org\/10.3109\/10428194.2016.1139703","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3529_CR44","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3324\/haematol.2016.145102","volume":"101","author":"V Camus","year":"2016","unstructured":"Camus V, Stamatoullas A, Mareschal S et al (2016) Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma. Haematologica 101(9):1094\u20131101. \n                    https:\/\/doi.org\/10.3324\/haematol.2016.145102","journal-title":"Haematologica"},{"issue":"9","key":"3529_CR45","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1373\/clinchem.2016.255315","volume":"62","author":"M Alcaide","year":"2016","unstructured":"Alcaide M, Yu S, Bushell K et al (2016) Multiplex droplet digital PCR quantification of recurrent somatic mutations in diffuse large B-cell and follicular lymphoma. Clin Chem 62(9):1238\u20131247. \n                    https:\/\/doi.org\/10.1373\/clinchem.2016.255315","journal-title":"Clin Chem"},{"key":"3529_CR46","doi-asserted-by":"publisher","unstructured":"Wedge E, Hansen JW, Garde C et al (2017) Global hypomethylation is an independent prognostic factor in diffuse large B cell lymphoma. Am J Hematol. \n                    https:\/\/doi.org\/10.1002\/ajh.24751","DOI":"10.1002\/ajh.24751"},{"issue":"40","key":"3529_CR47","doi-asserted-by":"publisher","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","volume":"112","author":"K Sun","year":"2015","unstructured":"Sun K, Jiang P, Chan KC et al (2015) Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 112(40):E5503\u2013E5512. \n                    https:\/\/doi.org\/10.1073\/pnas.1508736112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3529_CR48","doi-asserted-by":"publisher","first-page":"11815","DOI":"10.1038\/ncomms11815","volume":"7","author":"JJ Chabon","year":"2016","unstructured":"Chabon JJ, Simmons AD, Lovejoy AF et al (2016) Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun 7:11815. \n                    https:\/\/doi.org\/10.1038\/ncomms11815","journal-title":"Nat Commun"},{"key":"3529_CR49","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1038\/ncomms9839","volume":"6","author":"L Mattos-Arruda De","year":"2015","unstructured":"De Mattos-Arruda L, Mayor R, Ng CK et al (2015) Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun 6:8839. \n                    https:\/\/doi.org\/10.1038\/ncomms9839","journal-title":"Nat Commun"},{"issue":"31","key":"3529_CR50","doi-asserted-by":"publisher","first-page":"9704","DOI":"10.1073\/pnas.1511694112","volume":"112","author":"Y Wang","year":"2015","unstructured":"Wang Y, Springer S, Zhang M et al (2015) Detection of tumor-derived DNA in cerebrospinal fluid of patients with primary tumors of the brain and spinal cord. Proc Natl Acad Sci U S A 112(31):9704\u20139709. \n                    https:\/\/doi.org\/10.1073\/pnas.1511694112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3529_CR51","doi-asserted-by":"publisher","unstructured":"Sriram KB, Relan V, Clarke BE et al (2012) Pleural fluid cell-free DNA integrity index to identify cytologically negative malignant pleural effusions including mesotheliomas. BMC Cancer 12(1). \n                    https:\/\/doi.org\/10.1186\/1471-2407-12-428","DOI":"10.1186\/1471-2407-12-428"},{"issue":"1","key":"3529_CR52","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","volume":"70","author":"K Birkenkamp-Demtroder","year":"2016","unstructured":"Birkenkamp-Demtroder K, Nordentoft I, Christensen E et al (2016) Genomic alterations in liquid biopsies from patients with bladder cancer. Eur Urol 70(1):75\u201382. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.01.007","journal-title":"Eur Urol"},{"issue":"11","key":"3529_CR53","doi-asserted-by":"publisher","first-page":"E1317","DOI":"10.1073\/pnas.1500076112","volume":"112","author":"P Jiang","year":"2015","unstructured":"Jiang P, Chan CW, Chan KC et al (2015) Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad Sci U S A 112(11):E1317\u2013E1325. \n                    https:\/\/doi.org\/10.1073\/pnas.1500076112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"3529_CR54","doi-asserted-by":"publisher","first-page":"e1006162","DOI":"10.1371\/journal.pgen.1006162","volume":"12","author":"HR Underhill","year":"2016","unstructured":"Underhill HR, Kitzman JO, Hellwig S et al (2016) Fragment length of circulating tumor DNA. PLoS Genet 12(7):e1006162. \n                    https:\/\/doi.org\/10.1371\/journal.pgen.1006162","journal-title":"PLoS Genet"},{"issue":"4","key":"3529_CR55","first-page":"1659","volume":"61","author":"S Jahr","year":"2001","unstructured":"Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, Knippers R (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61(4):1659\u20131665","journal-title":"Cancer Res"},{"issue":"1","key":"3529_CR56","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.bbcan.2006.10.001","volume":"1775","author":"M Fleischhacker","year":"2007","unstructured":"Fleischhacker M, Schmidt B (2007) Circulating nucleic acids (CNAs) and cancer--a survey. Biochim Biophys Acta 1775(1):181\u2013232. \n                    https:\/\/doi.org\/10.1016\/j.bbcan.2006.10.001","journal-title":"Biochim Biophys Acta"},{"key":"3529_CR57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1196\/annals.1448.011","volume":"1137","author":"E Sunami","year":"2008","unstructured":"Sunami E, Vu AT, Nguyen SL, Giuliano AE, Hoon DS (2008) Quantification of LINE1 in circulating DNA as a molecular biomarker of breast cancer. Ann N Y Acad Sci 1137:171\u2013174. \n                    https:\/\/doi.org\/10.1196\/annals.1448.011","journal-title":"Ann N Y Acad Sci"},{"issue":"43","key":"3529_CR58","doi-asserted-by":"publisher","first-page":"13336","DOI":"10.1073\/pnas.1517494112","volume":"112","author":"I Vlaminck De","year":"2015","unstructured":"De Vlaminck I, Martin L, Kertesz M et al (2015) Noninvasive monitoring of infection and rejection after lung transplantation. Proc Natl Acad Sci U S A 112(43):13336\u201313341. \n                    https:\/\/doi.org\/10.1073\/pnas.1517494112","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"3529_CR59","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","volume":"129","author":"D Rossi","year":"2017","unstructured":"Rossi D, Diop F, Spaccarotella E et al (2017) Diffuse large B-cell lymphoma genotyping on the liquid biopsy. Blood 129(14):1947\u20131957. \n                    https:\/\/doi.org\/10.1182\/blood-2016-05-719641","journal-title":"Blood"},{"issue":"1","key":"3529_CR60","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/bjh.12439","volume":"163","author":"P Armand","year":"2013","unstructured":"Armand P, Oki Y, Neuberg DS et al (2013) Detection of circulating tumour DNA in patients with aggressive B-cell non-Hodgkin lymphoma. Br J Haematol 163(1):123\u2013126. \n                    https:\/\/doi.org\/10.1111\/bjh.12439","journal-title":"Br J Haematol"},{"issue":"5","key":"3529_CR61","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/bjh.14311","volume":"175","author":"AF Herrera","year":"2016","unstructured":"Herrera AF, Kim HT, Kong KA et al (2016) Next-generation sequencing-based detection of circulating tumour DNA after allogeneic stem cell transplantation for lymphoma. Br J Haematol 175(5):841\u2013850. \n                    https:\/\/doi.org\/10.1111\/bjh.14311","journal-title":"Br J Haematol"},{"issue":"8","key":"3529_CR62","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","volume":"20","author":"S Hohaus","year":"2009","unstructured":"Hohaus S, Giachelia M, Massini G et al (2009) Cell-free circulating DNA in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas. Ann Oncol 20(8):1408\u20131413. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdp006","journal-title":"Ann Oncol"},{"issue":"9","key":"3529_CR63","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1093\/annonc\/mdv272","volume":"26","author":"L Barault","year":"2015","unstructured":"Barault L, Amatu A, Bleeker FE et al (2015) Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Ann Oncol 26(9):1994\u20131999. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv272","journal-title":"Ann Oncol"},{"issue":"8","key":"3529_CR64","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1002\/ijc.30565","volume":"140","author":"C Bedin","year":"2017","unstructured":"Bedin C, Enzo MV, Del Bianco P, Pucciarelli S, Nitti D, Agostini M (2017) Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients. Int J Cancer 140(8):1888\u20131898. \n                    https:\/\/doi.org\/10.1002\/ijc.30565","journal-title":"Int J Cancer"},{"issue":"7598","key":"3529_CR65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/532269a","volume":"532","author":"KR Chi","year":"2016","unstructured":"Chi KR (2016) The tumour trail left in blood. Nature 532(7598):269\u2013271. \n                    https:\/\/doi.org\/10.1038\/532269a","journal-title":"Nature"},{"issue":"6","key":"3529_CR66","doi-asserted-by":"publisher","first-page":"djv409","DOI":"10.1093\/jnci\/djv409","volume":"108","author":"C Yuan","year":"2016","unstructured":"Yuan C, Clish CB, Wu C et al (2016) Circulating metabolites and survival among patients with pancreatic cancer. J Natl Cancer Inst 108(6):djv409. \n                    https:\/\/doi.org\/10.1093\/jnci\/djv409","journal-title":"J Natl Cancer Inst"},{"key":"3529_CR67","doi-asserted-by":"publisher","unstructured":"Perdigones N, Murtaza M (2017) Capturing tumor heterogeneity and clonal evolution in solid cancers using circulating tumor DNA analysis. Pharmacol Ther. \n                    https:\/\/doi.org\/10.1016\/j.pharmthera.2017.02.003","DOI":"10.1016\/j.pharmthera.2017.02.003"},{"issue":"7447","key":"3529_CR68","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature12065","volume":"497","author":"M Murtaza","year":"2013","unstructured":"Murtaza M, Dawson SJ, Tsui DW et al (2013) Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447):108\u2013112. \n                    https:\/\/doi.org\/10.1038\/nature12065","journal-title":"Nature"},{"issue":"224","key":"3529_CR69","doi-asserted-by":"publisher","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda C, Sausen M, Leary RJ et al (2014) Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 6(224):224ra224. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.3007094","journal-title":"Sci Transl Med"},{"issue":"13","key":"3529_CR70","doi-asserted-by":"publisher","first-page":"6871","DOI":"10.1158\/0008-5472.CAN-05-4556","volume":"66","author":"E Gormally","year":"2006","unstructured":"Gormally E, Vineis P, Matullo G et al (2006) TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. Cancer Res 66(13):6871\u20136876. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-4556","journal-title":"Cancer Res"},{"key":"3529_CR71","doi-asserted-by":"publisher","unstructured":"McMullen JRW, Selleck M, Wall NR, Senthil M (2017) Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget. \n                    https:\/\/doi.org\/10.18632\/oncotarget.16480","DOI":"10.18632\/oncotarget.16480"},{"key":"3529_CR72","doi-asserted-by":"publisher","unstructured":"Vidal J, Muinelo L, Dalmases A et al (2017) Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients. Ann Oncol. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdx125","DOI":"10.1093\/annonc\/mdx125"},{"issue":"4","key":"3529_CR73","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/ng.3805","volume":"49","author":"S Guo","year":"2017","unstructured":"Guo S, Diep D, Plongthongkum N, Fung HL, Zhang K, Zhang K (2017) Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet 49(4):635\u2013642. \n                    https:\/\/doi.org\/10.1038\/ng.3805","journal-title":"Nat Genet"},{"issue":"12","key":"3529_CR74","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1200\/JCO.2016.70.4627","volume":"35","author":"EL Christie","year":"2017","unstructured":"Christie EL, Fereday S, Doig K, Pattnaik S, Dawson SJ, Bowtell DDL (2017) Reversion of BRCA1\/2 germline mutations detected in circulating tumor DNA from patients with high-grade serous ovarian cancer. J Clin Oncol 35(12):1274\u20131280. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.70.4627","journal-title":"J Clin Oncol"},{"issue":"1","key":"3529_CR75","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-017-0412-4","volume":"10","author":"V Camus","year":"2017","unstructured":"Camus V, Miloudi H, Taly A, Sola B, Jardin F (2017) XPO1 in B cell hematological malignancies: from recurrent somatic mutations to targeted therapy. J Hematol Oncol 10(1):47. \n                    https:\/\/doi.org\/10.1186\/s13045-017-0412-4","journal-title":"J Hematol Oncol"},{"issue":"18","key":"3529_CR76","doi-asserted-by":"publisher","first-page":"16712","DOI":"10.18632\/oncotarget.3154","volume":"6","author":"S Dubois","year":"2015","unstructured":"Dubois S, Mareschal S, Picquenot JM et al (2015) Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy? Oncotarget 6(18):16712\u201316724. \n                    https:\/\/doi.org\/10.18632\/oncotarget.3154","journal-title":"Oncotarget"},{"issue":"24","key":"3529_CR77","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1002\/cncr.28964","volume":"120","author":"BS Sorensen","year":"2014","unstructured":"Sorensen BS, Wu L, Wei W, Tsai J, Weber B, Nexo E, Meldgaard P (2014) Monitoring of epidermal growth factor receptor tyrosine kinase inhibitor-sensitizing and resistance mutations in the plasma DNA of patients with advanced non-small cell lung cancer during treatment with erlotinib. Cancer 120(24):3896\u20133901. \n                    https:\/\/doi.org\/10.1002\/cncr.28964","journal-title":"Cancer"},{"issue":"6","key":"3529_CR78","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1158\/1078-0432.CCR-13-2482","volume":"20","author":"GR Oxnard","year":"2014","unstructured":"Oxnard GR, Paweletz CP, Kuang Y et al (2014) Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 20(6):1698\u20131705. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-2482","journal-title":"Clin Cancer Res"},{"issue":"4","key":"3529_CR79","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/annonc\/mdv005","volume":"26","author":"MP Morelli","year":"2015","unstructured":"Morelli MP, Overman MJ, Dasari A et al (2015) Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. Ann Oncol 26(4):731\u2013736. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv005","journal-title":"Ann Oncol"},{"key":"3529_CR80","doi-asserted-by":"publisher","unstructured":"Kridel R, Sehn LH, Gascoyne RD (2017) Can histologic transformation of follicular lymphoma be predicted and prevented? Blood. \n                    https:\/\/doi.org\/10.1182\/blood-2017-03-691345","DOI":"10.1182\/blood-2017-03-691345"},{"issue":"27","key":"3529_CR81","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059\u20133068. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"J Clin Oncol"},{"issue":"2","key":"3529_CR82","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1111\/bjh.13420","volume":"170","author":"HJ Adams","year":"2015","unstructured":"Adams HJ, Nievelstein RA, Kwee TC (2015) Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis. Br J Haematol 170(2):185\u2013191. \n                    https:\/\/doi.org\/10.1111\/bjh.13420","journal-title":"Br J Haematol"},{"issue":"9","key":"3529_CR83","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11864-016-0425-1","volume":"17","author":"M Kwok","year":"2016","unstructured":"Kwok M, Wu SP, Mo C, Summers T, Roschewski M (2016) Circulating tumor DNA to monitor therapy for aggressive B-cell lymphomas. Curr Treat Options in Oncol 17(9):47. \n                    https:\/\/doi.org\/10.1007\/s11864-016-0425-1","journal-title":"Curr Treat Options in Oncol"},{"issue":"2","key":"3529_CR84","doi-asserted-by":"publisher","first-page":"e66","DOI":"10.3324\/haematol.2015.132811","volume":"101","author":"S Luminari","year":"2016","unstructured":"Luminari S, Galimberti S, Versari A et al (2016) Positron emission tomography response and minimal residual disease impact on progression-free survival in patients with follicular lymphoma. A subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi. Haematologica 101(2):e66\u2013e68. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.132811","journal-title":"Haematologica"},{"issue":"3","key":"3529_CR85","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3324\/haematol.2015.134957","volume":"101","author":"M Cheminant","year":"2016","unstructured":"Cheminant M, Derrieux C, Touzart A et al (2016) Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study. Haematologica 101(3):336\u2013345. \n                    https:\/\/doi.org\/10.3324\/haematol.2015.134957","journal-title":"Haematologica"},{"issue":"3","key":"3529_CR86","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1182\/blood-2015-08-634816","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Wierda WG (2016) Eliminating minimal residual disease as a therapeutic end point: working toward cure for patients with CLL. Blood 127(3):279\u2013286. \n                    https:\/\/doi.org\/10.1182\/blood-2015-08-634816","journal-title":"Blood"},{"issue":"302","key":"3529_CR87","doi-asserted-by":"publisher","first-page":"302ra133","DOI":"10.1126\/scitranslmed.aab0021","volume":"7","author":"I Garcia-Murillas","year":"2015","unstructured":"Garcia-Murillas I, Schiavon G, Weigelt B et al (2015) Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med 7(302):302ra133. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aab0021","journal-title":"Sci Transl Med"},{"issue":"346","key":"3529_CR88","doi-asserted-by":"publisher","first-page":"346ra392","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C et al (2016) Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 8(346):346ra392. \n                    https:\/\/doi.org\/10.1126\/scitranslmed.aaf6219","journal-title":"Sci Transl Med"},{"issue":"5","key":"3529_CR89","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1182\/blood-2016-08-685073","volume":"129","author":"JB Cohen","year":"2017","unstructured":"Cohen JB, Behera M, Thompson CA, Flowers CR (2017) Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma. Blood 129(5):561\u2013564. \n                    https:\/\/doi.org\/10.1182\/blood-2016-08-685073","journal-title":"Blood"},{"issue":"34","key":"3529_CR90","doi-asserted-by":"publisher","first-page":"3983","DOI":"10.1200\/JCO.2015.63.5946","volume":"33","author":"JO Armitage","year":"2015","unstructured":"Armitage JO, Vose JM (2015) To surveil or not to surveil. J Clin Oncol 33(34):3983\u20133984. \n                    https:\/\/doi.org\/10.1200\/JCO.2015.63.5946","journal-title":"J Clin Oncol"},{"issue":"19","key":"3529_CR91","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1001\/jama.2016.4913","volume":"315","author":"C Nabhan","year":"2016","unstructured":"Nabhan C, Smith SM, Cifu AS (2016) Surveillance imaging in patients in remission from Hodgkin and diffuse large B-cell lymphoma. JAMA 315(19):2115\u20132116. \n                    https:\/\/doi.org\/10.1001\/jama.2016.4913","journal-title":"JAMA"},{"key":"3529_CR92","doi-asserted-by":"publisher","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A (2017) Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. \n                    https:\/\/doi.org\/10.1038\/nrclinonc.2017.14","DOI":"10.1038\/nrclinonc.2017.14"},{"issue":"12","key":"3529_CR93","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1515\/cclm-2014-1161","volume":"53","author":"F Malentacchi","year":"2015","unstructured":"Malentacchi F, Pizzamiglio S, Verderio P, Pazzagli M, Orlando C, Ciniselli CM, Gunther K, Gelmini S (2015) Influence of storage conditions and extraction methods on the quantity and quality of circulating cell-free DNA (ccfDNA): the SPIDIA-DNAplas external quality assessment experience. Clin Chem Lab Med 53(12):1935\u20131942. \n                    https:\/\/doi.org\/10.1515\/cclm-2014-1161","journal-title":"Clin Chem Lab Med"},{"issue":"10","key":"3529_CR94","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1158\/1078-0432.CCR-16-1691","volume":"23","author":"S Parpart-Li","year":"2016","unstructured":"Parpart-Li S, Bartlett B, Popoli M et al (2016) The effect of preservative and temperature on the analysis of circulating tumor DNA. Clin Cancer Res 23(10):2471\u20132477. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-1691","journal-title":"Clin Cancer Res"},{"key":"3529_CR95","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.cca.2013.05.022","volume":"424","author":"S Messaoudi El","year":"2013","unstructured":"El Messaoudi S, Rolet F, Mouliere F, Thierry AR (2013) Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 424:222\u2013230. \n                    https:\/\/doi.org\/10.1016\/j.cca.2013.05.022","journal-title":"Clin Chim Acta"},{"issue":"26","key":"3529_CR96","doi-asserted-by":"publisher","first-page":"6499","DOI":"10.1007\/s00216-014-7835-3","volume":"406","author":"AS Devonshire","year":"2014","unstructured":"Devonshire AS, Whale AS, Gutteridge A, Jones G, Cowen S, Foy CA, Huggett JF (2014) Towards standardisation of cell-free DNA measurement in plasma: controls for extraction efficiency, fragment size bias and quantification. Anal Bioanal Chem 406(26):6499\u20136512. \n                    https:\/\/doi.org\/10.1007\/s00216-014-7835-3","journal-title":"Anal Bioanal Chem"},{"issue":"2","key":"3529_CR97","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/s2352-3026(14)00039-8","volume":"2","author":"P Vandenberghe","year":"2015","unstructured":"Vandenberghe P, Wlodarska I, Tousseyn T et al (2015) Non-invasive detection of genomic imbalances in Hodgkin\/Reed-Sternberg cells in early and advanced stage Hodgkin\u2019s lymphoma by sequencing of circulating cell-free DNA: a technical proof-of-principle study. Lancet Haematol 2(2):e55\u2013e65. \n                    https:\/\/doi.org\/10.1016\/s2352-3026(14)00039-8","journal-title":"Lancet Haematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3529-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3529-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T09:09:57Z","timestamp":1589965797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3529-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,27]]},"references-count":97,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["3529"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3529-9","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,27]]},"assertion":[{"value":"6 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}